<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties manuscript?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-journal-id">0413675</journal-id><journal-id journal-id-type="pubmed-jr-id">4830</journal-id><journal-id journal-id-type="nlm-ta">J Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">J Infect Dis</journal-id><journal-title-group><journal-title>The Journal of infectious diseases</journal-title></journal-title-group><issn pub-type="ppub">0022-1899</issn><issn pub-type="epub">1537-6613</issn></journal-meta><article-meta><article-id pub-id-type="pmid">38687898</article-id><article-id pub-id-type="pmc">11646584</article-id><article-id pub-id-type="doi">10.1093/infdis/jiae220</article-id><article-id pub-id-type="manuscript">NIHMS2039646</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Reduced Effectiveness of Repeat Influenza Vaccination: Distinguishing Among Within-Season Waning, Recent Clinical Infection, and Subclinical Infection</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bi</surname><given-names>Qifang</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Dickerman</surname><given-names>Barbra A.</given-names></name><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Nguyen</surname><given-names>Huong Q.</given-names></name><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Martin</surname><given-names>Emily T.</given-names></name><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-3952-9230</contrib-id><name><surname>Gaglani</surname><given-names>Manjusha</given-names></name><xref rid="A5" ref-type="aff">5</xref><xref rid="A6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name><surname>Wernli</surname><given-names>Karen J.</given-names></name><xref rid="A7" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name><surname>Balasubramani</surname><given-names>G. K.</given-names></name><xref rid="A8" ref-type="aff">8</xref></contrib><contrib contrib-type="author"><name><surname>Flannery</surname><given-names>Brendan</given-names></name><xref rid="A9" ref-type="aff">9</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-1504-9213</contrib-id><name><surname>Lipsitch</surname><given-names>Marc</given-names></name><xref rid="A2" ref-type="aff">2</xref><xref rid="FN1" ref-type="author-notes">a</xref></contrib><contrib contrib-type="author"><name><surname>Cobey</surname><given-names>Sarah</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="FN1" ref-type="author-notes">a</xref></contrib><contrib contrib-type="author"><collab>US Flu Vaccine Effectiveness Network Investigators</collab><xref rid="FN2" ref-type="author-notes">b</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Ecology and Evolution, University of Chicago, Chicago, Illinois;</aff><aff id="A2"><label>2</label>Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts;</aff><aff id="A3"><label>3</label>Center for Clinical Epidemiology and Population Health, Marshfield Clinic Research Institute, Marshfield, Wisconsin;</aff><aff id="A4"><label>4</label>School of Public Health, University of Michigan, Ann Arbor, Michigan;</aff><aff id="A5"><label>5</label>Baylor Scott &#x00026; White Health, Temple, Texas;</aff><aff id="A6"><label>6</label>College of Medicine, Texas A&#x00026;M University, Temple;</aff><aff id="A7"><label>7</label>Kaiser Permanente Washington Health Research Institute, Seattle, Washington;</aff><aff id="A8"><label>8</label>Department of Epidemiology, School of Public Health, University of Pittsburgh, Pennsylvania;</aff><aff id="A9"><label>9</label>National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia</aff><author-notes><fn fn-type="equal" id="FN1"><label>a</label><p id="P1">M. L. and S. C. share equal contribution.</p></fn><fn fn-type="other" id="FN2"><label>b</label><p id="P2">Study group team members are listed in the Acknowledgments.</p></fn><fn fn-type="con" id="FN3"><p id="P3"><bold><italic toggle="yes">Author contributions</italic></bold>. Q. B., B. A. D., M. L., and S. C. conceived of the study. H. Q. N., E. T. M., M. G., K. J. W., G. K. B., and B. F. collected the data. Q. B. performed the analyses and generated all figures. Q. B., B. A. D., M. L., and S. C. wrote the manuscript. All authors revised the manuscript.</p></fn><corresp id="CR1">Correspondence: Qifang Bi, Department of Ecology and Evolution, University of Chicago, 114 Zoology Bldg, 1101 E 57th St, Chicago, IL 60637 (<email>Qifang.bi@gmail.com</email>); Sarah Cobey, Department of Ecology and Evolution, University of Chicago, 114 Zoology Bldg, 1101 E 57th St, Chicago, IL 60637 (<email>cobey@uchicago.edu</email>).</corresp></author-notes><pub-date pub-type="nihms-submitted"><day>12</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="ppub"><day>16</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>16</day><month>5</month><year>2025</year></pub-date><volume>230</volume><issue>6</issue><fpage>1309</fpage><lpage>1318</lpage><permissions><license><license-p>For commercial re-use, please contact <email>reprints@oup.com</email> for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site&#x02014;for further information please contact <email>journals.permissions@oup.com</email>.</license-p></license></permissions><abstract id="ABS1"><p id="P4">Studies have reported that prior-season influenza vaccination is associated with higher risk of clinical influenza infection among vaccinees. This effect might arise from incomplete consideration of within-season waning and recent infection. Using data from the US Flu Vaccine Effectiveness Network (2011&#x02013;2012 to 2018&#x02013;2019 seasons), we found that repeat vaccinees were vaccinated earlier in a season by 1 week. After accounting for waning VE, we determined that repeat vaccinees were still more likely to test positive for A(H3N2) (odds ratio, 1.11; 95% CI, 1.02&#x02013;1.21) but not influenza B or A(H1N1). We documented clinical infection influenced individuals&#x02019; decision to vaccinate in the following season while protecting against clinical infection of the same type/subtype. However, adjusting for recent documented clinical infections did not strongly influence the estimated effect of prior-season vaccination. In contrast, we found that adjusting for subclinical or undocumented infection could theoretically attenuate this effect. Additional investigation is needed to determine the impact of subclinical infections on vaccine effectiveness.</p></abstract><kwd-group><kwd>immunogenicity</kwd><kwd>infection block hypothesis</kwd><kwd>infection history</kwd><kwd>influenza vaccine</kwd><kwd>test negative design</kwd></kwd-group></article-meta></front><body><p id="P5">The World Health Organization recommends annual influenza vaccination of persons at high risk, with some countries recommending universal vaccination [<xref rid="R1" ref-type="bibr">1</xref>, <xref rid="R2" ref-type="bibr">2</xref>]. A controlled study in the 1970s first raised questions about repeated annual influenza vaccination, reporting that prior vaccination indirectly increased the risk of infection in the current season [<xref rid="R3" ref-type="bibr">3</xref>, <xref rid="R4" ref-type="bibr">4</xref>]. The phenomenon was not routinely investigated until a test-negative study in Canada [<xref rid="R5" ref-type="bibr">5</xref>], a vaccine trial in Hong Kong [<xref rid="R6" ref-type="bibr">6</xref>], and a household-based study in the United States [<xref rid="R7" ref-type="bibr">7</xref>] found differences in vaccine effectiveness (VE) and immunogenicity among repeat and nonrepeat vaccinees in the 2009&#x02013;2010 and 2010&#x02013;2011 seasons [<xref rid="R8" ref-type="bibr">8</xref>&#x02013;<xref rid="R14" ref-type="bibr">14</xref>]. Since then, increased infection risk against A(H3N2) in repeat vaccinees was observed in multiple seasons and countries [<xref rid="R7" ref-type="bibr">7</xref>, <xref rid="R11" ref-type="bibr">11</xref>, <xref rid="R12" ref-type="bibr">12</xref>, <xref rid="R13" ref-type="bibr">13</xref>, <xref rid="R15" ref-type="bibr">15</xref>, <xref rid="R16" ref-type="bibr">16</xref>], and it is less often reported for the less prevalent A(H1N1) and type B [<xref rid="R8" ref-type="bibr">8</xref>, <xref rid="R9" ref-type="bibr">9</xref>]. The increased risk of infection in repeat vaccinees has been associated with lack of confirmed influenza infection in the prior season [<xref rid="R17" ref-type="bibr">17</xref>].</p><p id="P6">Test-negative studies conducted in health care settings have become the standard way to evaluate vaccine protection. A test-negative design estimates VE by comparing vaccination coverage in persons with medically attended acute respiratory illness who test positive vs negative for influenza [<xref rid="R18" ref-type="bibr">18</xref>]. Several factors that may bias estimates of repeat vaccination effects in a test-negative design have not been considered.</p><p id="P7">Vaccine-induced protection against influenza virus infection wanes within a season [<xref rid="R19" ref-type="bibr">19</xref>&#x02013;<xref rid="R23" ref-type="bibr">23</xref>]. Consequently, the vaccine protection estimated among otherwise similar vaccinees may differ if the timing of vaccination is not considered. If repeat vaccinees tend to vaccinate substantially earlier in a season, waning protection could make the risk of infection among repeat vaccinees appear higher than in nonrepeat vaccinees. The rapidly changing risk of influenza incidence in a season may amplify the difference [<xref rid="R24" ref-type="bibr">24</xref>].</p><p id="P8">The infection block hypothesis [<xref rid="R4" ref-type="bibr">4</xref>, <xref rid="R25" ref-type="bibr">25</xref>&#x02013;<xref rid="R27" ref-type="bibr">27</xref>] suggests that prior vaccinations can block opportunities to experience immunogenic influenza virus infections, which can lead to more cross-reactive and durable immune responses than vaccination [<xref rid="R28" ref-type="bibr">28</xref>], especially when circulating viruses differ from vaccine strains [<xref rid="R29" ref-type="bibr">29</xref>, <xref rid="R30" ref-type="bibr">30</xref>]. If true, the infection block hypothesis could explain the increased risk of infection among repeat vaccinees vs nonrepeat vaccinees: prior-season vaccination could protect repeat vaccinees against prior-season infection, leaving them with less immune protection at the start of an influenza season and hence a higher incidence of clinical infection in that season as compared with nonrepeat vaccinees. The difference in risk between the groups can be amplified if recent infection improves vaccine immunogenicity and vaccine-induced protection [<xref rid="R29" ref-type="bibr">29</xref>], as recently observed for SARS-CoV-2 [<xref rid="R31" ref-type="bibr">31</xref>].</p><p id="P9">In epidemiologic terms [<xref rid="R32" ref-type="bibr">32</xref>], under the infection block hypothesis, infection in the previous season is a mediator between vaccination in the previous season and a clinical infection outcome in the current season. When we estimate the effect of repeated vaccination, infection in the previous season, acting as a mediator, does not inherently introduce bias. However, if infection in the previous season influences the decision to vaccinate in the current season as well as the probability of clinical infection in the current season, then it is a confounder that can bias the estimated effect of repeated vaccination on clinical infection. Because infection in the previous season may be a mediator and a confounder, appropriately adjusting for it requires an approach that can handle this treatment-confounder feedback, such as inverse probability weighting [<xref rid="R33" ref-type="bibr">33</xref>].</p><p id="P10">In this study, we first assessed the effect of repeated vaccination after accounting for intraseason waning of vaccine protection. We then assessed whether documented clinical infection in the prior season, a potential confounder, may have biased our estimate of the effect of repeated vaccination. Finally, we theoretically assessed the plausibility of the infection block hypothesis and enhanced VE from recent subclinical and undocumented infections as explanations for the repeat vaccination effect.</p><sec id="S1"><title>METHODS</title><sec id="S2"><title>Study Setting and Population</title><p id="P11">During the study period, the US Flu Vaccine Effectiveness Network consisted of 5 study sites in Wisconsin, Michigan, Washington, Pennsylvania, and Texas [<xref rid="R7" ref-type="bibr">7</xref>, <xref rid="R10" ref-type="bibr">10</xref>, <xref rid="R34" ref-type="bibr">34</xref>&#x02013;<xref rid="R36" ref-type="bibr">36</xref>] (<xref rid="SD1" ref-type="supplementary-material">Supplementary Section 1</xref>). The study was based on a test-negative design, estimating the odds of influenza infection in individuals who were vaccinated vs unvaccinated. During each enrollment season, outpatients aged &#x02265;6 months were eligible for recruitment if they presented with acute respiratory illness with symptom onset within the last 7 or 10 days, depending on the Flu Vaccine Effectiveness Network site. Each eligible patient completed an enrollment interview that included questions on status of influenza vaccination in the study enrollment season (the current season), influenza vaccination in the immediately preceding season (the previous season), demographic information, and underlying health conditions. Participants were tested for influenza by real-time reverse transcription polymerase chain reaction (rRT-PCR) assay. Influenza-positive samples were first typed and then A-subtyped or B-lineage-typed. For simplicity throughout, we refer to individuals with medically attended, PCR-confirmed symptomatic influenza virus infection as having &#x0201c;clinical infection.&#x0201d; Influenza vaccination status was confirmed by reviewing immunization records and state registries.</p><p id="P12">We analyzed data collected over 8 seasons (2011&#x02013;2012 through 2018&#x02013;2019) from all 5 sites. We excluded those who were vaccinated within 14 days of illness onset, for consistency with prior analyses. We also excluded anyone who received &#x0003e;1 dose each season before symptom onset and were &#x0003c;1 year of age at enrollment.</p><p id="P13">To study the impact of clinical infection history, we additionally obtained enrollment history and real-time reverse transcription PCR testing history from the Marshfield Clinic Health System (MCHS), the US Flu Vaccine Effectiveness Network site in Wisconsin. The analyses using exclusively MCHS data are described in the subsection titled &#x0201c;<xref rid="S5" ref-type="sec">Adjustment for clinical infection history</xref>&#x0201d; of the Methods, and the results are shown in the subsection titled &#x0201c;Impact of Clinical Infection History&#x0201d; of the Results. The study design and the definition of clinical infection were consistent over time. As the primary outpatient and inpatient care provider in its catchment area, MCHS could collect data on enrollment and testing history that are not available from other sites [<xref rid="R37" ref-type="bibr">37</xref>]. In particular, participant data are linked across seasons. We analyzed data from the MCHS over 12 seasons (2007&#x02013;2008 through 2018&#x02013;2019). Eligible patients who were not approached or chose not to enroll were not included in the study. Therefore, we referred to &#x02018;documented&#x02019; and &#x02018;undocumented&#x02019; clinical infections in our analyses to emphasize that the study did not enroll all individuals who met the syndromic definition of influenza-like illness and would have tested positive in the prior season if they had been enrolled.</p></sec><sec id="S3"><title>Statistical Analyses</title><sec id="S4"><title>Accounting for Within-Season Waning of Vaccine Protection</title><p id="P14">Using data from the 5 sites in the US Flu Vaccine Effectiveness Network, we first determined whether the timing of vaccination differed between repeat and nonrepeat vaccinees by fitting a linear regression model.</p><p id="P15">Using logistic regression models, we then estimated the relative odds of documented clinical infection among repeat vaccinees with reference to nonrepeat vaccinees after adjusting for time of vaccination in the current season (to account for the waning of vaccine protection; <xref rid="SD1" ref-type="supplementary-material">Supplementary Section 3</xref>). The study outcome is documented type/subtype-specific PCR-confirmed clinical infection. Independent variables are as follows: an indicator for having been vaccinated 2&#x02013;9, 10&#x02013;13, 14&#x02013;17, 18&#x02013;21, or &#x0003e;21 weeks before symptom onset in the current season regardless of prior-season vaccination status (with categorization consistent with Ray et al [<xref rid="R19" ref-type="bibr">19</xref>]); a dichotomous indicator for having been vaccinated only in the prior season; a dichotomous indicator for having been vaccinated in the current season and the prior season; and age group, sex, comorbidity, influenza season, study site, and calendar month of symptom onset.</p></sec><sec id="S5"><title>Adjustment for Clinical Infection History</title><p id="P16">Because MCHS was the only site that had linked participants&#x02019; previous study enrollment and infection history, only data from MCHS could be used to assess the impact of clinical infection history.</p><p id="P17">To determine how a clinical infection in the current season is associated with documented clinical infection with the same and other types/subtypes in prior seasons, we assessed the odds ratio of clinical infection in the current season among individuals with no prior documented clinical infections or with documented clinical infections 3 to 5 or &#x02265;6 seasons ago with reference to those whose last documented clinical infection was 1 or 2 seasons before the current season (<xref rid="SD1" ref-type="supplementary-material">Supplementary Section 4</xref>).</p><p id="P18">Using logistic regression models, we then assessed whether documented clinical infections in the previous season influenced the decision to vaccinate in the current season. The dependent variable was vaccination in the current season. The model was stratified by previous-season vaccination status and adjusted for age group, sex, comorbidity, and an indicator of vaccination frequency (<xref rid="SD1" ref-type="supplementary-material">Supplementary Section 4</xref>).</p><p id="P19">Next, we estimated the effect of repeated vaccination after adjusting for the documented clinical infection status of any type/subtype in the previous season (<xref rid="SD1" ref-type="supplementary-material">Supplementary Section 4</xref>). To handle the treatment-confounder feedback, we used inverse probability weighting to account for documented clinical infection status of any type/subtype in the previous season, using regression to adjust for baseline covariates. Weights were calculated as the inverse of each person&#x02019;s probability of being vaccinated in each season given one&#x02019;s previous vaccination status, documented clinical infection status in the prior season, and baseline covariates (ie, sex, age group, comorbidities, influenza season). These weights were then &#x0201c;stabilized&#x0201d; by using the probabilities of being vaccinated (given the vaccination history) and the aforementioned baseline covariates (excluding infection status in the prior season).</p></sec><sec id="S6"><title>Impact of Subclinical and Undocumented Infection</title><p id="P20">To understand how history of subclinical or undocumented infection (ie, infections not detected by the US Flu Vaccine Effectiveness Network) may affect the estimated effect of repeated vaccination, we evaluated the proportion of repeat and nonrepeat vaccinees who would have had to have been subclinically infected or have had undocumented infection in the previous season to reproduce the estimated effect of repeated vaccination, assuming that the infection block hypothesis from subclinical or undocumented infection was the only explanation for the observed elevated risk. We demonstrate that the results are consistent with the hypothesis of enhanced vaccine immunogenicity postinfection.</p><p id="P21">To achieve this objective, we built a theoretical model and created a pseudo-population of repeat and nonrepeat vaccinees with various infection statuses in the previous seasons (<xref rid="SD1" ref-type="supplementary-material">Supplementary Section 5</xref>). We derived the relationship between rates of subclinical or undocumented infections in repeat and nonrepeat vaccinees given various degrees of effectiveness of subclinical or undocumented infection against future clinical infection (30%, 50%, and 70% reductions in clinical infection risk). We varied assumptions about the protection conferred by documented clinical, subclinical, or undocumented infection in the prior season against future infection. Based on estimates from prior studies [<xref rid="R38" ref-type="bibr">38</xref>, <xref rid="R39" ref-type="bibr">39</xref>], we varied clinical attack rates in vaccinated and unvaccinated individuals, assuming either low clinical incidence (1% and 2% for vaccinated and unvaccinated, respectively) or high (3% and 6%).</p><p id="P22">The study obtained institutional review board approval at participating institutions and the Centers for Disease Control and Prevention.</p></sec></sec></sec><sec id="S7"><title>RESULTS</title><p id="P23">Between the 2011&#x02013;2012 and 2018&#x02013;2019 seasons, participants enrolled in the US Flu Vaccine Effectiveness Network contributed 61 943 visits, of which 55 728 (90.0%) met the inclusion criteria of our analyses. Of those visits, 50.2% (27 986/55 728) were by individuals who had received 1 dose of the current seasonal influenza vaccine &#x02265;14 days prior to the onset date of illness (<xref rid="SD1" ref-type="supplementary-material">Supplementary Figure 1.1</xref>). Among those vaccinated &#x02265;14 days prior to illness onset, 73.7% (20 630/27 986) of visits were by participants who were vaccinated at least once in the previous season, whom we refer to as repeat vaccinees (<xref rid="SD1" ref-type="supplementary-material">Supplementary Table 1.1</xref>).</p><sec id="S8"><title>Impact of Waning Vaccine Protection</title><p id="P24">On average, repeat vaccinees of similar age, sex, and comorbidities were vaccinated 1.1 weeks (95% CI, 1.0&#x02013;1.2) earlier than nonrepeat vaccinees (<xref rid="F1" ref-type="fig">Figure 1A</xref>). Adjusting for the timing of vaccination in the current season did not notably change the marked repeat vaccination effect for A/H3N2 and had little to no effect for A/H1N1pdm09 and type B (<xref rid="F1" ref-type="fig">Figure 1B</xref>; <xref rid="SD1" ref-type="supplementary-material">Supplementary Figure 3.3</xref> shows variation in estimates by season and site; <xref rid="SD1" ref-type="supplementary-material">Supplementary Figure 3.5</xref> shows that results did not vary significantly by age group).</p><p id="P25">In models accounting for the timing of vaccination and previous season vaccination, we observed that odds of documented clinical infection against all 3 types/subtypes increased with time since current season vaccination (<xref rid="F1" ref-type="fig">Figure 1C</xref>). When compared with individuals not vaccinated in either season (who had the highest risk of testing positive), current-season vaccinees who vaccinated 2 to 9 weeks before testing had lower odds (odds ratio [OR], 0.29; 95% CI, .23&#x02013;.35) for A/H1N1pdm09-associated illness than those vaccinated 18 to 21 weeks before testing (OR, 0.66; 95% CI, .56&#x02013;.78). In the 2014&#x02013;2015 season, when there was a mismatch between the A/H3N2 component and the circulating strains, the odds of documented clinical infection decreased with time from vaccination in Wisconsin (<xref rid="SD1" ref-type="supplementary-material">Supplementary Figure 3.1</xref>).</p></sec><sec id="S9"><title>Impact of Documented Clinical Infection History</title><p id="P26">Prior documented clinical infections of the homologous type/subtype protected against clinical infections of type B or A/H3N2, with more recent documented infections conferring stronger protection (<xref rid="F2" ref-type="fig">Figure 2A</xref>): those clinically infected with type B &#x0003e;6 seasons ago had 3.60 times (95% CI, 1.08&#x02013;11.9) the odds of testing positive for type B in the current season than those who were clinically infected in the previous 1 or 2 seasons (<xref rid="F2" ref-type="fig">Figure 2A</xref>). A similar trend emerged for documented clinical infections against A/H3N2 (OR, 32.4; 95% CI, 4.4&#x02013;242; <xref rid="F2" ref-type="fig">Figure 2A</xref>). We did not find documented clinical infections of a heterologous type/subtype to be protective (<xref rid="SD1" ref-type="supplementary-material">Supplementary Figure 4.1</xref>). Due to the limited number of A/H1N1pdm09 infections during our enrollment period, we could not assess the impact of homologous clinical infection with A/H1N1pdm09.</p><p id="P27">We found that having a documented clinical influenza virus infection in the previous season appeared to influence the decision to vaccinate in the current season. Individuals unvaccinated in the previous season were more likely to vaccinate in the current season (OR, 1.30; 95% CI, 1.18&#x02013;1.44) if they had documented clinical infection in the previous season than if they had not. However, those who became infected after being vaccinated in the previous season were as likely to be unvaccinated in the current season as those not infected (OR, 0.96; 95% CI, .85&#x02013;1.10), with the exception of the oldest group, which tended to vaccinate again (<xref rid="F2" ref-type="fig">Figure 2B</xref>).</p><p id="P28">Adjusting for confounding by documented clinical infection in the previous season had little influence on the estimated effect of repeated vaccination (<xref rid="F2" ref-type="fig">Figure 2C</xref>). After adjustment, repeat vaccinees enrolled during the 2008&#x02013;2009 season and between the 2010&#x02013;2011 and 2018&#x02013;2019 seasons had 1.29 times (95% CI, .96&#x02013;1.71) the odds of testing positive for A/H1N1dpm09 than those who were vaccinated in only the current season. Accounting for documented clinical infection history did not significantly change the estimated effect of repeated vaccination against A/H3N2 (from 1.02 [95% CI, .84&#x02013;1.23] to 1.06 [95% CI, .87&#x02013;1.31] postadjustment) or type B (from 1.18 [95% CI, .91&#x02013;1.53] to 1.17 [95% CI, .92&#x02013;1.52] postadjustment). Excluding the 194 individuals who presented with acute respiratory illness but refused enrollment in the previous season did not significantly change the results (<xref rid="SD1" ref-type="supplementary-material">Supplementary Figure 4.2</xref>). Not adjusting for waning vaccine protection in the weighted outcome model yielded similar results (<xref rid="SD1" ref-type="supplementary-material">Supplementary Figure 4.3</xref>, <xref rid="SD1" ref-type="supplementary-material">Supplementary Section 4</xref>).</p></sec><sec id="S10"><title>Impact of Documented and Undocumented Clinical and Subclinical Infection History</title><sec id="S11"><title>Infection Block Hypothesis</title><p id="P29">In the previous section, we estimated that repeat vaccinees had a 10% increase (approximate OR, 1.1) in the odds of current-season documented clinical infection, an effect that could be partially mediated by documented clinical infection in the prior season, a version of the infection block hypothesis. In this section, we use a theoretical model to explore the degree to which subclinical or undocumented infection&#x02014;which would not be observed in any of the data sets that we consider&#x02014;could fully explain the observed repeat vaccination effect.</p><p id="P30">To produce the estimated effect of repeated vaccination in the US Flu Vaccine Effectiveness Network (ie, for clinical infection comparing repeat with nonrepeat vaccinees against A/H3N2 or type B; OR, 1.1), nonrepeat vaccinees would have to be subclinically infected or have undocumented infection in the prior season at a substantially higher rate than repeat vaccinees (<xref rid="F3" ref-type="fig">Figure 3</xref>, <xref rid="SD1" ref-type="supplementary-material">Supplementary Figure 5.1</xref>). For example, if subclinical or undocumented infection reduces the probability of next-season clinical infection by 70% (dark green curve in <xref rid="F3" ref-type="fig">Figure 3A</xref>), approximately 5% of repeat vaccinees and approximately 15% of nonrepeat vaccinees would have to have been subclinically infected or have undocumented infection in the prior season to observe the estimated effect.</p><p id="P31">For thoroughness, we showed that prior-season documented clinical infection is unlikely to be an important mediator in this relationship between prior-season vaccination and the odds of current-season clinical infection (<xref rid="SD1" ref-type="supplementary-material">Supplementary Section 6</xref>, <xref rid="SD1" ref-type="supplementary-material">Supplementary Figure 6.1</xref>). When compared with estimates from a setting of low clinical incidence, in a high-incidence setting, we expect a greater excess of clinical infections in the current season among repeat vaccinees vs nonrepeat vaccinees (<xref rid="SD1" ref-type="supplementary-material">Supplementary Figure 5.2</xref>).</p></sec><sec id="S12"><title>Enhanced Vaccine Immunogenicity Hypothesis</title><p id="P32">If recent infection improves vaccine immunogenicity and thus vaccine-induced protection, a smaller difference in rates of subclinical or undocumented infection between repeat and nonrepeat vaccinees would generate the same estimated effect of repeated vaccination against documented clinical infection in the current season (<xref rid="SD1" ref-type="supplementary-material">Supplementary Figure 5.3</xref>). For example, in the scenario described in the previous section, we would observe the expected effect of repeated vaccination (OR, 1.1) when the difference in the rate of subclinical or documented infection between repeat and nonrepeat vaccinees is 10% (eg, approximately 5% and 15%, respectively), assuming that subclinical or undocumented infection reduces the probability of future clinical infection by 70%. But if recent infection boosts VE from 50% to 76%, a smaller difference in attack rate from subclinical or undocumented infection (approximately 5% in repeat vaccinees and 12% in nonrepeat vaccinees) and weaker protection from subclinical or undocumented infection (from 70% to 30%) can produce the same estimated effect.</p></sec></sec></sec><sec id="S13"><title>DISCUSSION</title><p id="P33">Observational studies [<xref rid="R7" ref-type="bibr">7</xref>&#x02013;<xref rid="R13" ref-type="bibr">13</xref>, <xref rid="R15" ref-type="bibr">15</xref>, <xref rid="R16" ref-type="bibr">16</xref>], mostly based on the test-negative design [<xref rid="R8" ref-type="bibr">8</xref>&#x02013;<xref rid="R13" ref-type="bibr">13</xref>, <xref rid="R15" ref-type="bibr">15</xref>, <xref rid="R16" ref-type="bibr">16</xref>], have provided critical information on influenza VE. These studies can have biases and uncontrolled confounding that affect inference, including inference of VE in different subpopulations [<xref rid="R34" ref-type="bibr">34</xref>, <xref rid="R40" ref-type="bibr">40</xref>&#x02013;<xref rid="R43" ref-type="bibr">43</xref>]. Reduced VE in repeat vaccinees has been a troubling, intermittent, and largely unexplained phenomenon [<xref rid="R8" ref-type="bibr">8</xref>, <xref rid="R9" ref-type="bibr">9</xref>]. We studied a component phenomenon, which is that the absolute risk (or odds) of infection among vaccinees in the current season is less if they were unvaccinated last season than if they were vaccinated last season. We observed waning of vaccine protection and repeat vaccinees&#x02019; tendency to vaccinate earlier within a season as compared with nonrepeat vaccinees. We showed that clinical infection affects one&#x02019;s decision to vaccinate in the next season and that documented clinical infections in the past 1 or 2 seasons strongly protect against reinfection. However, these potentially biasing factors&#x02014;prior-season clinical infection and timing of vaccination&#x02014;could not fully explain the higher risk of clinical infection in the repeat vs nonrepeat vaccinees in our study population. We showed that the residual repeat vaccination effect might be explained by different rates of subclinical infection or undocumented infection between repeat and nonrepeat vaccinees via 2 proposed mechanisms: the infection block hypothesis [<xref rid="R4" ref-type="bibr">4</xref>, <xref rid="R25" ref-type="bibr">25</xref>&#x02013;<xref rid="R27" ref-type="bibr">27</xref>] and enhanced vaccine immunogenicity and protection postinfection [<xref rid="R29" ref-type="bibr">29</xref>, <xref rid="R44" ref-type="bibr">44</xref>]. The difference in rates of subclinical or undocumented infection between the groups and its variation from one season to the next might thus underlie variability in estimated effects of repeated vaccination.</p><p id="P34">Mostly due to lack of data, clinical infection history has typically not been accounted for when estimating influenza VE. We found that accounting for documented clinical infection history did not substantially change the estimated effect of repeat vaccination, indicating that confounding by prior-season documented clinical infection may not fully explain the elevated odds of infection among repeat vaccinees. Aside from a potential role as a confounder, we found documented clinical infection unlikely to act as an important mediator. Verifying the finding in surveillance data requires methods that can tease apart the direct and indirect effects of vaccination after taking into account the interaction of vaccination and infection over a multiyear period.</p><p id="P35">The sensitivity of the estimated effect of repeated vaccination to differences in subclinical attack rates and infection-associated protection suggests a possible explanation for the observed variability in the estimated effect of repeat vaccination and other VE measures across locations and time. There is well-known spatiotemporal variation in the sizes of influenza epidemics and in circulating clades that could affect the amount of protection conferred by infection in different populations. Our results suggest a need to try to account more precisely for past infections so that VE estimates can be compared across populations stratified by similar infection history. Longitudinal cohort studies that involve blood collection, active surveillance, and sequencing can be useful for identifying subclinical infections, and coupling these observations with health care&#x02013;seeking behavior and PCR testing can help test the infection block and enhanced immunogenicity hypotheses [<xref rid="R45" ref-type="bibr">45</xref>]. Eventually, stratification on infection history may be possible through surrogate immune markers.</p><p id="P36">The study has several limitations. Throughout our analysis, we assumed that influenza vaccination with any type of influenza vaccine confers complete protection in a subset of vaccinees. We did not consider &#x0201c;leaky&#x0201d; vaccine effects, where vaccines are partially protective in all recipients, which can lead to an observed decline in VE estimates even when vaccine protection does not wane [<xref rid="R46" ref-type="bibr">46</xref>]. Although the test-negative study, by selecting only patients who seek medical care, is designed to reduce the difference in health-seeking behavior between cases and noncases, it does not eliminate it [<xref rid="R41" ref-type="bibr">41</xref>]. In the study of prior clinical infection history using the data from Marshfield, only a fraction of all individuals presenting for care with influenza-like illness participated each season. Therefore, those with documented clinical infection in a prior season represent a fraction of all individuals who met the syndromic definition of influenza-like illness and would have tested positive in the prior season if they had enrolled in the prior season. We did not explore birth cohort effects or the effects of antigenic distance on protection [<xref rid="R47" ref-type="bibr">47</xref>&#x02013;<xref rid="R50" ref-type="bibr">50</xref>]. Since we assumed that people without enrollment records in the previous season were not clinically infected, some of them may have been misclassified.</p><p id="P37">The practical benefits of annual vaccination programs should not be extrapolated from this analysis of the relative risk of infection in repeat vaccinees vs nonrepeat vaccinees. The choice between an annual and nonannual vaccination program should be based on assessments of the infection risk among all repeat and nonrepeat vaccinees as well as those who are unvaccinated. Our analysis does not compare the risk of infection between repeat vaccinees and those vaccinated in the prior season only, who would be part of a hypothetical nonannual vaccination program.</p><p id="P38">Our study provides evidence that 2 potential factors&#x02014;timing of vaccination and documented clinical infection history&#x02014;cannot fully explain the increased infection risk in repeat vaccinees as compared with nonrepeat vaccinees. Documented clinical infection history is further unlikely to act as a strong mediator to explain the repeated vaccination effect. Instead, under reasonable assumptions, the infection block and enhanced immunogenicity hypotheses involving subclinical or undocumented infection in the previous season may explain the effect, thus acting as a potential mediator. Estimation of VE requires careful consideration of time since vaccination and infection history of different subpopulations.</p></sec><sec sec-type="supplementary-material" id="SM1"><title>Supplementary Material</title><supplementary-material id="SD1" position="float" content-type="local-data"><label>supplemental</label><media xlink:href="NIHMS2039646-supplement-supplemental.zip" id="d67e589" position="anchor"/></supplementary-material></sec></body><back><ack id="S15"><title>Acknowledgments.</title><p id="P40">We thank Benjamin A. Cowling for comments. Investigators and collaborators in the US Flu Vaccine Effectiveness Network Investigators include the following: Baylor Scott &#x00026; White Health&#x02014;Kempapura Murthy, Chandni Raiyani, Kayan Dunnigan, Muffadal Mamawala; Centers for Disease Control and Infection&#x02014;Jessie R. Chung, Manish Patel; Henry Ford Medical Center&#x02014;Lois Lamerato; Kaiser Permanente Washington&#x02014;Michael L. Jackson, C. Hallie Phillips, Erika Kiniry; Marshfield Clinic Research Institute&#x02014;Edward A. Belongia, Jennifer P. King; University of Michigan&#x02014;Arnold S. Monto; University of Pittsburgh&#x02014;Richard K. Zimmerman, Mary Patricia Nowalk, Krissy Moehling Geffel.</p><sec id="S16"><title>Financial support.</title><p id="P41">This study was supported by the National Institute of Allergy and Infectious Diseases (NIAID) Collaborative Influenza Vaccine Innovation Centers (CIVICs) (contract 75N93019C00051 to S. C. and Q. B.); and the National Institutes of Health to the University of Michigan (grant 1R01GM139926 to M. L.).</p></sec></ack><fn-group><fn id="FN4"><p id="P42">Supplementary Data</p><p id="P43"><xref rid="SD1" ref-type="supplementary-material">Supplementary materials</xref> are available at <italic toggle="yes">The Journal of Infectious Diseases</italic> online (<ext-link xlink:href="http://jid.oxfordjournals.org/" ext-link-type="uri">http://jid.oxfordjournals.org/</ext-link>). <xref rid="SD1" ref-type="supplementary-material">Supplementary materials</xref> consist of data provided by the author that are published to benefit the reader. The posted materials are not copyedited. The contents of all <xref rid="SD1" ref-type="supplementary-material">supplementary data</xref> are the sole responsibility of the authors. Questions or messages regarding errors should be addressed to the author.</p></fn><fn fn-type="COI-statement" id="FN5"><p id="P44"><bold><italic toggle="yes">Potential conflicts of interest</italic></bold>. All authors: No reported conflicts.</p><p id="P45">All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.</p></fn></fn-group><sec sec-type="data-availability" id="S14"><title>Data availability.</title><p id="P39">Data and relevant code are available at <ext-link xlink:href="https://github.com/cobeylab/FluVE_repeatvac_public" ext-link-type="uri">https://github.com/cobeylab/FluVE_repeatvac_public</ext-link>. The analyses were conducted in R version 4.1.1.</p></sec><ref-list><title>References</title><ref id="R1"><label>1.</label><mixed-citation publication-type="journal"><article-title>Vaccines against influenza WHO position paper&#x02014;November 2012</article-title>. <source>Wkly Epidemiol Rec</source>
<year>2012</year>; <volume>87</volume>:<fpage>461</fpage>&#x02013;<lpage>76</lpage>.<pub-id pub-id-type="pmid">23210147</pub-id>
</mixed-citation></ref><ref id="R2"><label>2.</label><mixed-citation publication-type="journal"><name><surname>Principi</surname><given-names>N</given-names></name>, <name><surname>Camilloni</surname><given-names>B</given-names></name>, <name><surname>Esposito</surname><given-names>S</given-names></name>; <collab>ESCMID Vaccine Study Group (EVASG)</collab>. <article-title>Influenza immunization policies: which could be the main reasons for differences among countries?</article-title>
<source>Hum Vaccin Immunother</source>
<year>2018</year>; <volume>14</volume>:<fpage>684</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="pmid">29227734</pub-id>
</mixed-citation></ref><ref id="R3"><label>3.</label><mixed-citation publication-type="journal"><name><surname>Hoskins</surname><given-names>TW</given-names></name>, <name><surname>Davies</surname><given-names>J</given-names></name>, <name><surname>Smith</surname><given-names>AJ</given-names></name>, <name><surname>Allchin</surname><given-names>A</given-names></name>, <name><surname>Miller</surname><given-names>C</given-names></name>, <name><surname>Pollock</surname><given-names>TM</given-names></name>. <article-title>Influenza at Christ&#x02019;s Hospital: March, 1974</article-title>. <source>Lancet</source>
<year>1976</year>; <volume>307</volume>:<fpage>105</fpage>&#x02013;<lpage>8</lpage>.</mixed-citation></ref><ref id="R4"><label>4.</label><mixed-citation publication-type="journal"><name><surname>Hoskins</surname><given-names>TW</given-names></name>, <name><surname>Davies</surname><given-names>JR</given-names></name>, <name><surname>Smith</surname><given-names>AJ</given-names></name>, <name><surname>Miller</surname><given-names>CL</given-names></name>, <name><surname>Allchin</surname><given-names>A</given-names></name>. <article-title>Assessment of inactivated influenza-A vaccine after three outbreaks of influenza A at Christ&#x02019;s Hospital</article-title>. <source>Lancet</source>
<year>1979</year>; <volume>313</volume>:<fpage>33</fpage>&#x02013;<lpage>5</lpage>.</mixed-citation></ref><ref id="R5"><label>5.</label><mixed-citation publication-type="journal"><name><surname>Skowronski</surname><given-names>DM</given-names></name>, <name><surname>Janjua</surname><given-names>NZ</given-names></name>, <name><surname>De Serres</surname><given-names>G</given-names></name>, <etal/>
<article-title>A sentinel platform to evaluate influenza vaccine effectiveness and new variant circulation, Canada 2010&#x02013;2011 season</article-title>. <source>Clin Infect Dis</source>
<year>2012</year>; <volume>55</volume>:<fpage>332</fpage>&#x02013;<lpage>42</lpage>.<pub-id pub-id-type="pmid">22539661</pub-id>
</mixed-citation></ref><ref id="R6"><label>6.</label><mixed-citation publication-type="journal"><name><surname>Ng</surname><given-names>S</given-names></name>, <name><surname>Fang</surname><given-names>VJ</given-names></name>, <name><surname>Ip</surname><given-names>DKM</given-names></name>, <etal/>
<article-title>Humoral antibody response after receipt of inactivated seasonal influenza vaccinations one year apart in children</article-title>. <source>Pediatr Infect Dis J</source>
<year>2012</year>; <volume>31</volume>:<fpage>964</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">22683675</pub-id>
</mixed-citation></ref><ref id="R7"><label>7.</label><mixed-citation publication-type="journal"><name><surname>Ohmit</surname><given-names>SE</given-names></name>, <name><surname>Petrie</surname><given-names>JG</given-names></name>, <name><surname>Malosh</surname><given-names>RE</given-names></name>, <etal/>
<article-title>Influenza vaccine effectiveness in the community and the household</article-title>. <source>Clin Infect Dis</source>
<year>2013</year>; <volume>56</volume>:<fpage>1363</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">23413420</pub-id>
</mixed-citation></ref><ref id="R8"><label>8.</label><mixed-citation publication-type="journal"><name><surname>Belongia</surname><given-names>EA</given-names></name>, <name><surname>Skowronski</surname><given-names>DM</given-names></name>, <name><surname>McLean</surname><given-names>HQ</given-names></name>, <name><surname>Chambers</surname><given-names>C</given-names></name>, <name><surname>Sundaram</surname><given-names>ME</given-names></name>, <name><surname>De Serres</surname><given-names>G</given-names></name>. <article-title>Repeated annual influenza vaccination and vaccine effectiveness: review of evidence</article-title>. <source>Expert Rev Vaccines</source>
<year>2017</year>; <volume>16</volume>:<fpage>723</fpage>&#x02013;<lpage>36</lpage>.</mixed-citation></ref><ref id="R9"><label>9.</label><mixed-citation publication-type="journal"><name><surname>Ramsay</surname><given-names>LC</given-names></name>, <name><surname>Buchan</surname><given-names>SA</given-names></name>, <name><surname>Stirling</surname><given-names>RG</given-names></name>, <etal/>
<article-title>The impact of repeated vaccination on influenza vaccine effectiveness: a systematic review and meta-analysis</article-title>. <source>BMC Med</source>
<year>2019</year>; <volume>17</volume>:<fpage>9</fpage>.<pub-id pub-id-type="pmid">30626399</pub-id>
</mixed-citation></ref><ref id="R10"><label>10.</label><mixed-citation publication-type="journal"><name><surname>McLean</surname><given-names>HQ</given-names></name>, <name><surname>Thompson</surname><given-names>MG</given-names></name>, <name><surname>Sundaram</surname><given-names>ME</given-names></name>, <etal/>
<article-title>Impact of repeated vaccination on vaccine effectiveness against influenza A(H3N2) and B during 8 seasons</article-title>. <source>Clin Infect Dis</source>
<year>2014</year>; <volume>59</volume>:<fpage>1375</fpage>&#x02013;<lpage>85</lpage>.<pub-id pub-id-type="pmid">25270645</pub-id>
</mixed-citation></ref><ref id="R11"><label>11.</label><mixed-citation publication-type="journal"><name><surname>Ohmit</surname><given-names>SE</given-names></name>, <name><surname>Thompson</surname><given-names>MG</given-names></name>, <name><surname>Petrie</surname><given-names>JG</given-names></name>, <etal/>
<article-title>Influenza vaccine effectiveness in the 2011&#x02013;2012 season: protection against each circulating virus and the effect of prior vaccination on estimates</article-title>. <source>Clin Infect Dis</source>
<year>2014</year>; <volume>58</volume>:<fpage>319</fpage>&#x02013;<lpage>27</lpage>.<pub-id pub-id-type="pmid">24235265</pub-id>
</mixed-citation></ref><ref id="R12"><label>12.</label><mixed-citation publication-type="journal"><name><surname>Skowronski</surname><given-names>DM</given-names></name>, <name><surname>Chambers</surname><given-names>C</given-names></name>, <name><surname>Sabaiduc</surname><given-names>S</given-names></name>, <etal/>
<article-title>A perfect storm: impact of genomic variation and serial vaccination on low influenza vaccine effectiveness during the 2014&#x02013;2015 season</article-title>. <source>Clin Infect Dis</source>
<year>2016</year>; <volume>63</volume>:<fpage>21</fpage>&#x02013;<lpage>32</lpage>.<pub-id pub-id-type="pmid">27025838</pub-id>
</mixed-citation></ref><ref id="R13"><label>13.</label><mixed-citation publication-type="journal"><name><surname>Valenciano</surname><given-names>M</given-names></name>, <name><surname>Kissling</surname><given-names>E</given-names></name>, <name><surname>Reuss</surname><given-names>A</given-names></name>, <etal/>
<article-title>Vaccine effectiveness in preventing laboratory-confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE multicentre case-control study, Europe 2014/15</article-title>. <source>Euro Surveill</source>
<year>2016</year>; <volume>21</volume>:<comment>ii=30139.</comment></mixed-citation></ref><ref id="R14"><label>14.</label><mixed-citation publication-type="journal"><name><surname>Kissling</surname><given-names>E</given-names></name>, <name><surname>Pozo</surname><given-names>F</given-names></name>, <name><surname>Buda</surname><given-names>S</given-names></name>, <etal/>
<article-title>Low 2018/19 vaccine effectiveness against influenza A(H3N2) among 15&#x02013;64-year-olds in Europe: exploration by birth cohort</article-title>. <source>Euro Surveill</source>
<year>2019</year>; <volume>24</volume>:<fpage>e1900604</fpage>.</mixed-citation></ref><ref id="R15"><label>15.</label><mixed-citation publication-type="journal"><name><surname>McLean</surname><given-names>HQ</given-names></name>, <name><surname>Thompson</surname><given-names>MG</given-names></name>, <name><surname>Sundaram</surname><given-names>ME</given-names></name>, <etal/>
<article-title>Influenza vaccine effectiveness in the United States during 2012&#x02013;2013: variable protection by age and virus type</article-title>. <source>J Infect Dis</source>
<year>2015</year>; <volume>211</volume>:<fpage>1529</fpage>&#x02013;<lpage>40</lpage>.<pub-id pub-id-type="pmid">25406334</pub-id>
</mixed-citation></ref><ref id="R16"><label>16.</label><mixed-citation publication-type="journal"><name><surname>Kissling</surname><given-names>E</given-names></name>, <name><surname>Pozo</surname><given-names>F</given-names></name>, <name><surname>Buda</surname><given-names>S</given-names></name>, <etal/>
<article-title>Low 2018/19 vaccine effectiveness against influenza A(H3N2) among 15&#x02013;64-year-olds in Europe: exploration by birth cohort</article-title>. <source>Euro Surveill</source>
<year>2019</year>; <volume>24</volume>:<fpage>e1900604</fpage>.</mixed-citation></ref><ref id="R17"><label>17.</label><mixed-citation publication-type="journal"><name><surname>Saito</surname><given-names>N</given-names></name>, <name><surname>Komori</surname><given-names>K</given-names></name>, <name><surname>Suzuki</surname><given-names>M</given-names></name>, <etal/>
<article-title>Negative impact of prior influenza vaccination on current influenza vaccination among people infected and notinfected in prior season: A test-negative case-control study in Japan</article-title>. <source>Vaccine</source>
<year>2017</year>; <volume>35</volume>:<fpage>687</fpage>&#x02013;<lpage>693</lpage>.<pub-id pub-id-type="pmid">28043738</pub-id>
</mixed-citation></ref><ref id="R18"><label>18.</label><mixed-citation publication-type="journal"><name><surname>Ferdinands</surname><given-names>JM</given-names></name>, <name><surname>Shay</surname><given-names>DK</given-names></name>. <article-title>Magnitude of potential biases in a simulated case-control study of the effectiveness of influenza vaccination</article-title>. <source>Clin Infect Dis</source>
<year>2012</year>; <volume>54</volume>:<fpage>25</fpage>&#x02013;<lpage>32</lpage>.<pub-id pub-id-type="pmid">22095567</pub-id>
</mixed-citation></ref><ref id="R19"><label>19.</label><mixed-citation publication-type="journal"><name><surname>Ray</surname><given-names>GT</given-names></name>, <name><surname>Lewis</surname><given-names>N</given-names></name>, <name><surname>Klein</surname><given-names>NP</given-names></name>, <etal/>
<article-title>Intraseason waning of influenza vaccine effectiveness</article-title>. <source>Clin Infect Dis</source>
<year>2019</year>; <volume>68</volume>: <fpage>1623</fpage>&#x02013;<lpage>30</lpage>.<pub-id pub-id-type="pmid">30204855</pub-id>
</mixed-citation></ref><ref id="R20"><label>20.</label><mixed-citation publication-type="journal"><name><surname>Ferdinands</surname><given-names>JM</given-names></name>, <name><surname>Gaglani</surname><given-names>M</given-names></name>, <name><surname>Martin</surname><given-names>ET</given-names></name>, <etal/>
<article-title>Waning vaccine effectiveness against influenza-associated hospitalizations among adults, 2015&#x02013;2016 to 2018&#x02013;2019, United States Hospitalized Adult Influenza Vaccine Effectiveness Network</article-title>. <source>Clin Infect Dis</source>
<year>2021</year>; <volume>73</volume>:<fpage>726</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">33462610</pub-id>
</mixed-citation></ref><ref id="R21"><label>21.</label><mixed-citation publication-type="journal"><name><surname>Young</surname><given-names>B</given-names></name>, <name><surname>Sadarangani</surname><given-names>S</given-names></name>, <name><surname>Jiang</surname><given-names>L</given-names></name>, <name><surname>Wilder-Smith</surname><given-names>A</given-names></name>, <name><surname>Chen</surname><given-names>MI-C</given-names></name>. <article-title>Duration of influenza vaccine effectiveness: a systematic review, meta-analysis, and meta-regression of test-negative design case-control studies</article-title>. <source>J Infect Dis</source>
<year>2018</year>; <volume>217</volume>: <fpage>731</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="pmid">29220496</pub-id>
</mixed-citation></ref><ref id="R22"><label>22.</label><mixed-citation publication-type="journal"><name><surname>Jim&#x000e9;nez-Jorge</surname><given-names>S</given-names></name>, <name><surname>de Mateo</surname><given-names>S</given-names></name>, <name><surname>Delgado-Sanz</surname><given-names>C</given-names></name>, <etal/>
<article-title>Effectiveness of influenza vaccine against laboratory-confirmed influenza, in the late 2011&#x02013;2012 season in Spain, among population targeted for vaccination</article-title>. <source>BMC Infect Dis</source>
<year>2013</year>; <volume>13</volume>:<fpage>441</fpage>.<pub-id pub-id-type="pmid">24053661</pub-id>
</mixed-citation></ref><ref id="R23"><label>23.</label><mixed-citation publication-type="journal"><name><surname>Ferdinands</surname><given-names>JM</given-names></name>, <name><surname>Fry</surname><given-names>AM</given-names></name>, <name><surname>Reynolds</surname><given-names>S</given-names></name>, <etal/>
<article-title>Intraseason waning of influenza vaccine protection: evidence from the US Influenza Vaccine Effectiveness Network, 2011&#x02013;12 through 2014&#x02013;15</article-title>. <source>Clin Infect Dis</source>
<year>2017</year>; <volume>64</volume>:<fpage>544</fpage>&#x02013;<lpage>50</lpage>.<pub-id pub-id-type="pmid">28039340</pub-id>
</mixed-citation></ref><ref id="R24"><label>24.</label><mixed-citation publication-type="journal"><name><surname>Fox</surname><given-names>SJ</given-names></name>, <name><surname>Miller</surname><given-names>JC</given-names></name>, <name><surname>Meyers</surname><given-names>LA</given-names></name>. <article-title>Seasonality in risk of pandemic influenza emergence</article-title>. <source>PLoS Comput Biol</source>
<year>2017</year>; <volume>13</volume>: <fpage>e1005749</fpage>.<pub-id pub-id-type="pmid">29049288</pub-id>
</mixed-citation></ref><ref id="R25"><label>25.</label><mixed-citation publication-type="journal"><name><surname>Skowronski</surname><given-names>DM</given-names></name>, <name><surname>Janjua</surname><given-names>NZ</given-names></name>, <name><surname>Hottes</surname><given-names>TS</given-names></name>, <name><surname>De Serres</surname><given-names>G</given-names></name>. <article-title>Mechanism for seasonal vaccine effect on pandemic H1N1 risk remains uncertain</article-title>. <source>Clin Infect Dis</source>
<year>2011</year>; <volume>52</volume>:<fpage>831</fpage>&#x02013;<lpage>2</lpage>.<pub-id pub-id-type="pmid">21367740</pub-id>
</mixed-citation></ref><ref id="R26"><label>26.</label><mixed-citation publication-type="journal"><name><surname>Skowronski</surname><given-names>DM</given-names></name>, <name><surname>De Serres</surname><given-names>G</given-names></name>, <name><surname>Crowcroft</surname><given-names>NS</given-names></name>, <etal/>
<article-title>Association between the 2008&#x02013;09 seasonal influenza vaccine and pandemic H1N1 illness during spring-summer 2009: four observational studies from Canada</article-title>. <source>PLoS Med</source>
<year>2010</year>; <volume>7</volume>:<fpage>e1000258</fpage>.<pub-id pub-id-type="pmid">20386731</pub-id>
</mixed-citation></ref><ref id="R27"><label>27.</label><mixed-citation publication-type="journal"><name><surname>Cowling</surname><given-names>BJ</given-names></name>, <name><surname>Ng</surname><given-names>S</given-names></name>, <name><surname>Ma</surname><given-names>ESK</given-names></name>, <etal/>
<article-title>Protective efficacy of seasonal influenza vaccination against seasonal and pandemic influenza virus infection during 2009 in Hong Kong</article-title>. <source>Clin Infect Dis</source>
<year>2010</year>; <volume>51</volume>:<fpage>1370</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">21067351</pub-id>
</mixed-citation></ref><ref id="R28"><label>28.</label><mixed-citation publication-type="journal"><name><surname>Ranjeva</surname><given-names>S</given-names></name>, <name><surname>Subramanian</surname><given-names>R</given-names></name>, <name><surname>Fang</surname><given-names>VJ</given-names></name>, <etal/>
<article-title>Age-specific differences in the dynamics of protective immunity to influenza</article-title>. <source>Nat Commun</source>
<year>2019</year>; <volume>10</volume>:<fpage>1660</fpage>.<pub-id pub-id-type="pmid">30971703</pub-id>
</mixed-citation></ref><ref id="R29"><label>29.</label><mixed-citation publication-type="journal"><name><surname>Auladell</surname><given-names>M</given-names></name>, <name><surname>Phuong</surname><given-names>HVM</given-names></name>, <name><surname>Mai</surname><given-names>LTQ</given-names></name>, <etal/>
<article-title>Influenza virus infection history shapes antibody responses to influenza vaccination</article-title>. <source>Nat Med</source>
<year>2022</year>; <volume>28</volume>:<fpage>363</fpage>&#x02013;<lpage>72</lpage>.<pub-id pub-id-type="pmid">35177857</pub-id>
</mixed-citation></ref><ref id="R30"><label>30.</label><mixed-citation publication-type="journal"><name><surname>Krammer</surname><given-names>F</given-names></name>
<article-title>The human antibody response to influenza A virus infection and vaccination</article-title>. <source>Nat Rev Immunol</source>
<year>2019</year>; <volume>19</volume>:<fpage>383</fpage>&#x02013;<lpage>97</lpage>.<pub-id pub-id-type="pmid">30837674</pub-id>
</mixed-citation></ref><ref id="R31"><label>31.</label><mixed-citation publication-type="journal"><name><surname>Hall</surname><given-names>V</given-names></name>, <name><surname>Foulkes</surname><given-names>S</given-names></name>, <name><surname>Insalata</surname><given-names>F</given-names></name>, <etal/>
<article-title>Protection against SARS-CoV-2 after COVID-19 vaccination and previous infection</article-title>. <source>N Engl J Med</source>
<year>2022</year>; <volume>386</volume>:<fpage>1207</fpage>&#x02013;<lpage>20</lpage>.<pub-id pub-id-type="pmid">35172051</pub-id>
</mixed-citation></ref><ref id="R32"><label>32.</label><mixed-citation publication-type="journal"><name><surname>VanderWeele</surname><given-names>TJ</given-names></name>. <article-title>Explanation in causal inference: developments in mediation and interaction</article-title>. <source>Int J Epidemiol</source>
<year>2016</year>; <volume>45</volume>:<fpage>1904</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">27864406</pub-id>
</mixed-citation></ref><ref id="R33"><label>33.</label><mixed-citation publication-type="book"><name><surname>Hernan</surname><given-names>MA</given-names></name>, <name><surname>Robins</surname><given-names>JM</given-names></name>. <source>Causal inference</source>. <publisher-loc>Boca Raton, FL</publisher-loc>: <publisher-name>CRC Press</publisher-name>, <year>2019</year>.</mixed-citation></ref><ref id="R34"><label>34.</label><mixed-citation publication-type="journal"><name><surname>Gaglani</surname><given-names>M</given-names></name>, <name><surname>Pruszynski</surname><given-names>J</given-names></name>, <name><surname>Murthy</surname><given-names>K</given-names></name>, <etal/>
<article-title>Influenza vaccine effectiveness against 2009 pandemic influenza A(H1N1) virus differed by vaccine type during 2013&#x02013;2014 in the United States</article-title>. <source>J Infect Dis</source>
<year>2016</year>; <volume>213</volume>:<fpage>1546</fpage>&#x02013;<lpage>56</lpage>.<pub-id pub-id-type="pmid">26743842</pub-id>
</mixed-citation></ref><ref id="R35"><label>35.</label><mixed-citation publication-type="journal"><name><surname>Zimmerman</surname><given-names>RK</given-names></name>, <name><surname>Nowalk</surname><given-names>MP</given-names></name>, <name><surname>Chung</surname><given-names>J</given-names></name>, <etal/>
<article-title>2014&#x02013;2015 Influenza vaccine effectiveness in the United States by vaccine type</article-title>. <source>Clin Infect Dis</source>
<year>2016</year>; <volume>63</volume>:<fpage>1564</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="pmid">27702768</pub-id>
</mixed-citation></ref><ref id="R36"><label>36.</label><mixed-citation publication-type="journal"><name><surname>Jackson</surname><given-names>ML</given-names></name>, <name><surname>Chung</surname><given-names>JR</given-names></name>, <name><surname>Jackson</surname><given-names>LA</given-names></name>, <etal/>
<article-title>Influenza vaccine effectiveness in the United States during the 2015&#x02013;2016 season</article-title>. <source>N Engl J Med</source>
<year>2017</year>; <volume>377</volume>:<fpage>534</fpage>&#x02013;<lpage>43</lpage>.<pub-id pub-id-type="pmid">28792867</pub-id>
</mixed-citation></ref><ref id="R37"><label>37.</label><mixed-citation publication-type="journal"><name><surname>Kieke</surname><given-names>AL</given-names></name>, <name><surname>Kieke</surname><given-names>B</given-names></name>, <name><surname>Kopitzke</surname><given-names>SL</given-names></name>, <etal/>
<article-title>Validation of health event capture in the Marshfield Epidemiologic Study Area</article-title>. <source>Clin Med Res</source>
<year>2015</year>; <volume>13</volume>:<fpage>103</fpage>&#x02013;<lpage>11</lpage>.<pub-id pub-id-type="pmid">25487238</pub-id>
</mixed-citation></ref><ref id="R38"><label>38.</label><mixed-citation publication-type="journal"><name><surname>Cohen</surname><given-names>C</given-names></name>, <name><surname>Kleynhans</surname><given-names>J</given-names></name>, <name><surname>Moyes</surname><given-names>J</given-names></name>, <etal/>
<article-title>Asymptomatic transmission and high community burden of seasonal influenza in an urban and a rural community in South Africa, 2017&#x02013;18 (PHIRST): a population cohort study</article-title>. <source>Lancet Glob Health</source>
<year>2021</year>; <volume>9</volume>:<fpage>e863</fpage>&#x02013;<lpage>74</lpage>.<pub-id pub-id-type="pmid">34019838</pub-id>
</mixed-citation></ref><ref id="R39"><label>39.</label><mixed-citation publication-type="journal"><name><surname>Jackson</surname><given-names>ML</given-names></name>, <name><surname>Jackson</surname><given-names>LA</given-names></name>, <name><surname>Kieke</surname><given-names>B</given-names></name>, <etal/>
<article-title>Incidence of medically attended influenza infection and cases averted by vaccination, 2011/2012 and 2012/2013 influenza seasons</article-title>. <source>Vaccine</source>
<year>2015</year>; <volume>33</volume>:<fpage>5181</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">26271827</pub-id>
</mixed-citation></ref><ref id="R40"><label>40.</label><mixed-citation publication-type="journal"><name><surname>Lipsitch</surname><given-names>M</given-names></name>, <name><surname>Tchetgen Tchetgen</surname><given-names>E</given-names></name>, <name><surname>Cohen</surname><given-names>T</given-names></name>. <article-title>Negative controls: a tool for detecting confounding and bias in observational studies</article-title>. <source>Epidemiology</source>
<year>2010</year>; <volume>21</volume>:<fpage>383</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">20335814</pub-id>
</mixed-citation></ref><ref id="R41"><label>41.</label><mixed-citation publication-type="journal"><name><surname>Sullivan</surname><given-names>SG</given-names></name>, <name><surname>Tchetgen Tchetgen</surname><given-names>EJ</given-names></name>, <name><surname>Cowling</surname><given-names>BJ</given-names></name>. <article-title>Theoretical basis of the test-negative study design for assessment of influenza vaccine effectiveness</article-title>. <source>Am J Epidemiol</source>
<year>2016</year>; <volume>184</volume>:<fpage>345</fpage>&#x02013;<lpage>53</lpage>.<pub-id pub-id-type="pmid">27587721</pub-id>
</mixed-citation></ref><ref id="R42"><label>42.</label><mixed-citation publication-type="journal"><name><surname>Chua</surname><given-names>H</given-names></name>, <name><surname>Feng</surname><given-names>S</given-names></name>, <name><surname>Lewnard</surname><given-names>JA</given-names></name>, <etal/>
<article-title>The use of test-negative controls to monitor vaccine effectiveness: a systematic review of methodology</article-title>. <source>Epidemiology</source>
<year>2020</year>; <volume>31</volume>:<fpage>43</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="pmid">31609860</pub-id>
</mixed-citation></ref><ref id="R43"><label>43.</label><mixed-citation publication-type="journal"><name><surname>Jackson</surname><given-names>ML</given-names></name>, <name><surname>Nelson</surname><given-names>JC</given-names></name>. <article-title>The test-negative design for estimating influenza vaccine effectiveness</article-title>. <source>Vaccine</source>
<year>2013</year>; <volume>31</volume>: <fpage>2165</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">23499601</pub-id>
</mixed-citation></ref><ref id="R44"><label>44.</label><mixed-citation publication-type="journal"><name><surname>Altarawneh</surname><given-names>HN</given-names></name>, <name><surname>Chemaitelly</surname><given-names>H</given-names></name>, <name><surname>Ayoub</surname><given-names>HH</given-names></name>, <etal/>
<article-title>Effects of previous infection and vaccination on symptomatic omicron infections</article-title>. <source>N Engl J Med</source>
<year>2022</year>; <volume>387</volume>:<fpage>21</fpage>&#x02013;<lpage>34</lpage>.<pub-id pub-id-type="pmid">35704396</pub-id>
</mixed-citation></ref><ref id="R45"><label>45.</label><mixed-citation publication-type="journal"><name><surname>Monto</surname><given-names>AS</given-names></name>, <name><surname>DeJonge</surname><given-names>PM</given-names></name>, <name><surname>Callear</surname><given-names>AP</given-names></name>, <etal/>
<article-title>Coronavirus occurrence and transmission over 8 years in the HIVE cohort of households in Michigan</article-title>. <source>J Infect Dis</source>
<year>2020</year>; <volume>222</volume>:<fpage>9</fpage>&#x02013;<lpage>16</lpage>.<pub-id pub-id-type="pmid">32246136</pub-id>
</mixed-citation></ref><ref id="R46"><label>46.</label><mixed-citation publication-type="journal"><name><surname>Tokars</surname><given-names>JI</given-names></name>, <name><surname>Patel</surname><given-names>MM</given-names></name>, <name><surname>Foppa</surname><given-names>IM</given-names></name>, <name><surname>Reed</surname><given-names>C</given-names></name>, <name><surname>Fry</surname><given-names>AM</given-names></name>, <name><surname>Ferdinands</surname><given-names>JM</given-names></name>. <article-title>Waning of measured influenza vaccine effectiveness over time: the potential contribution of leaky vaccine effect</article-title>. <source>Clin Infect Dis</source>
<year>2020</year>; <volume>71</volume>:<fpage>e633</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="pmid">32227109</pub-id>
</mixed-citation></ref><ref id="R47"><label>47.</label><mixed-citation publication-type="journal"><name><surname>Smith</surname><given-names>DJ</given-names></name>, <name><surname>Forrest</surname><given-names>S</given-names></name>, <name><surname>Ackley</surname><given-names>DH</given-names></name>, <name><surname>Perelson</surname><given-names>AS</given-names></name>. <article-title>Variable efficacy of repeated annual influenza vaccination</article-title>. <source>Proc Natl Acad Sci U S A</source>
<year>1999</year>; <volume>96</volume>:<fpage>14001</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">10570188</pub-id>
</mixed-citation></ref><ref id="R48"><label>48.</label><mixed-citation publication-type="journal"><name><surname>Arevalo</surname><given-names>P</given-names></name>, <name><surname>McLean</surname><given-names>HQ</given-names></name>, <name><surname>Belongia</surname><given-names>EA</given-names></name>, <name><surname>Cobey</surname><given-names>S</given-names></name>. <article-title>Earliest infections predict the age distribution of seasonal influenza A cases</article-title>. <source>Elife</source>
<year>2020</year>; <volume>9</volume>:<fpage>e50060</fpage>.<pub-id pub-id-type="pmid">32633233</pub-id>
</mixed-citation></ref><ref id="R49"><label>49.</label><mixed-citation publication-type="journal"><name><surname>Skowronski</surname><given-names>DM</given-names></name>, <name><surname>Chambers</surname><given-names>C</given-names></name>, <name><surname>De Serres</surname><given-names>G</given-names></name>, <etal/>
<article-title>Serial vaccination and the antigenic distance hypothesis: effects on influenza vaccine effectiveness during A(H3N2) epidemics in Canada, 2010&#x02013;2011 to 2014&#x02013;2015</article-title>. <source>J Infect Dis</source>
<year>2017</year>; <volume>215</volume>:<fpage>1059</fpage>&#x02013;<lpage>99</lpage>.<pub-id pub-id-type="pmid">28180277</pub-id>
</mixed-citation></ref><ref id="R50"><label>50.</label><mixed-citation publication-type="journal"><name><surname>Flannery</surname><given-names>B</given-names></name>, <name><surname>Smith</surname><given-names>C</given-names></name>, <name><surname>Garten</surname><given-names>RJ</given-names></name>, <etal/>
<article-title>Influence of birth cohort on effectiveness of 2015&#x02013;2016 influenza vaccine against medically attended illness due to 2009 pandemic influenza A(H1N1) virus in the United States</article-title>. <source>J Infect Dis</source>
<year>2018</year>; <volume>218</volume>:<fpage>189</fpage>&#x02013;<lpage>96</lpage>.<pub-id pub-id-type="pmid">29361005</pub-id>
</mixed-citation></ref></ref-list></back><floats-group><fig position="float" id="F1"><label>Figure 1.</label><caption><p id="P46">That repeat vaccinees vaccinate earlier in a season, which increases their susceptibility to infection due to waning vaccine protection, does not explain their higher odds of documented clinical infection as compared with nonrepeat vaccinees. <italic toggle="yes">A</italic>, Average calendar week of vaccination among repeat and nonrepeat vaccinees over the study enrollment seasons. Repeat vaccinees consistently get vaccinated earlier than nonrepeat vaccinees. <italic toggle="yes">B</italic>, Adjusted odds ratio for documented clinical infection among individuals vaccinated this season stratified by whether they were also vaccinated in the prior season or not (repeat or nonrepeat vaccinees), before (estimates using the &#x0201c;base models&#x0201d;) and after (estimates using the &#x0201c;waning adjusted models&#x0201d;) adjustment for the timing of vaccination within a season. Site- and season-specific data are shown in <xref rid="SD1" ref-type="supplementary-material">Supplementary Figure 3.3</xref>. <italic toggle="yes">C</italic>, Adjusted odds ratio of documented clinical infection comparing individuals vaccinated in the current season by weeks, but not in the previous season, before testing positive with respect to those not vaccinated in either season. Error bars indicate 95% CI. Site- and season-specific data are shown in <xref rid="SD1" ref-type="supplementary-material">Supplementary Figure 3.1</xref>, and age-specific data are shown in <xref rid="SD1" ref-type="supplementary-material">Supplementary Figure 3.5</xref>. See <xref rid="SD1" ref-type="supplementary-material">Supplementary Section 3</xref> for detailed definitions of the quantities reported here.</p></caption><graphic xlink:href="nihms-2039646-f0001" position="float"/></fig><fig position="float" id="F2"><label>Figure 2.</label><caption><p id="P47">Recent documented clinical infections, which induce nonvaccinees to vaccinate the next season and which can protect against clinical reinfection for years, cannot explain the effect of repeated vaccination. <italic toggle="yes">A</italic>, Association between recent documented clinical infections and odds of clinical infection in the current influenza season. More distant documented clinical infections of the homologous subtype are associated with higher odds of current-season documented clinical infection. <italic toggle="yes">B</italic>, Tendency to switch vaccination status in the current influenza season after documented clinical infection in the previous season. When compared with individuals without confirmed infections, unvaccinated individuals who were clinically infected in the previous season were more likely to vaccinate in the current season. <italic toggle="yes">C</italic>, Estimated effect of repeat vaccination after adjusting for recent documented clinical infections. Adjusted odds ratio for clinical infection comparing repeat vaccinees with nonrepeat vaccinees before (estimates from the &#x0201c;base models&#x0201d;) and after (estimates from the &#x0201c;models adjusted for documented clinical infection history&#x0201d;) adjustment for documented clinical infection status in the previous season via inverse probability weighting. Results stratified by age group are shown in <xref rid="SD1" ref-type="supplementary-material">Supplementary Figure 4.4</xref>. They suggest a marginally higher adjusted odds of infection with statistical significance in repeat vaccinees &#x0003e;19 years old for H1N1. Adjustment did not significantly affect the estimates. Error bars indicate 95% CIs.</p></caption><graphic xlink:href="nihms-2039646-f0002" position="float"/></fig><fig position="float" id="F3"><label>Figure 3.</label><caption><p id="P48">Subclinical or undocumented infection might be able to explain the effect of repeated vaccination, aligning with the hypotheses of (<italic toggle="yes">A</italic>) infection block and (<italic toggle="yes">B</italic>) enhanced immunogenicity. <italic toggle="yes">A</italic>, The fraction of repeat and nonrepeat vaccinees who would need to have been subclinically infected or have undocumented infection in the previous season to reproduce the estimated effect of repeated vaccination in the US Flu Vaccine Effectiveness Network (ie, OR, 1.1), given various assumptions of predetermined protection against clinical infection after subclinical or undocumented infection (30%, 50%, 70%). See <xref rid="SD1" ref-type="supplementary-material">Supplementary Section 5</xref> for detailed methods. Under this hypothesis, subclinical or undocumented infection is more common among those unvaccinated in the previous season (green lines above the 45&#x000b0; line) and reduces risk of infection this season. Only the plausible range of attack rate of subclinical and undocumented infection among repeat vaccinees (x-axis) and nonrepeat vaccinees (y-axis; 0%&#x02013;50%) are shown in the figure. <italic toggle="yes">B</italic>, The absolute increase in vaccine effectiveness from a baseline of 50% needed to reproduce the estimated effect of repeated vaccination in the US Flu Vaccine Effectiveness Network (OR, 1.1). Under this hypothesis, vaccination this season is more effective in those infected subclinically or with undocumented infection in the previous season, who are (as in panel <italic toggle="yes">A</italic>) more common among those unvaccinated in the previous season. The figure shows the scenario where the effectiveness of subclinical or undocumented infection against future clinical infection is 30%. The uncolored portion of the figure represents the population where a boost in vaccine effectiveness after infection will not generate the estimated effect of repeated vaccination (OR, 1.1). The results in both panels assume that vaccine effectiveness against clinical infection is 50%; the clinical attack rate among vaccinees in a season is 1%; the current-season clinical attack rate among the subset of current-season vaccinees not infected in the previous season is 1.5%; and documented clinical infection in the previous season perfectly protects against clinical infection in the following season.</p></caption><graphic xlink:href="nihms-2039646-f0003" position="float"/></fig></floats-group></article>